Literature DB >> 6174541

Augmentation of natural killer (NK) cell activity by a streptococcal preparation, OK-432, in patients with malignant tumors.

H Wakasugi, K Oshimi, M Miyata, Y Morioka.   

Abstract

Recently, a streptococcal preparation, OK-432 has been used successfully as an immunopotentiator for immunotherapy in patients with malignant tumors in Japan. In this paper, we report that the administration of OK-432 augments the cytotoxic activity of peripheral blood lymphoid cells against a natural killer (NK) cell-sensitive erythroleukemic cell line, K562, in tumor patients. In patients before or after surgery, sufficient amounts of OK-432 strongly augmented the cytotoxic activity within 3 days after the initial administration of OK-432. Thereafter the levels of cytotoxicity declined rapidly. The administration of a lower dose of OK-432 gave a lower increase in cytotoxicity. Enhanced cytotoxicity occurred with the reintroduction of OK-432 but remained at lower levels of activity. Characterization and fractionation of OK-432-induced effector cells revealed that the augmented cytotoxicity seemed to be carried mainly by NK cells. A low titer of interferon was detected in 3 of 10 patients within 72 hr after the first inoculation of the agent. Furthermore, we discuss the potency of OK-432 for the induction of interferon in detail.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6174541     DOI: 10.1007/BF00922757

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  26 in total

1.  Inhibition of tumor growth in vivo and in vitro by macrophages from rats treated with a streptococcal preparation, OK-432.

Authors:  Y Ishii; H Yamaoka; K Toh; K Kikuchi
Journal:  Gan       Date:  1976-02

2.  Inhibitory effect of a streptococcal preparation (OK-432) on the nucleic acid synthesis in tumor cells in vitro.

Authors:  T Ono; S Kurata; K Wakabayashi; Y Sugawara; M Saito
Journal:  Gan       Date:  1973-02

3.  Tumor-inhibitory effect of a streptococcal preparation (NSC-B116209).

Authors:  S Tsukagoshi; Y Sakurai; H Sato; S Akiba T SUZUKI
Journal:  Cancer Chemother Rep       Date:  1972-02

4.  Drug-induced restoration of cutaneous delayed hypersensitivity in anergic patients with cancer.

Authors:  D Tripodi; L C Parks; J Brugmans
Journal:  N Engl J Med       Date:  1973-08-16       Impact factor: 91.245

5.  Effect of short-term levamisole therapy on delayed hypersensitivity.

Authors:  Y Hirshaut; C M Pinsky; I Frydecka; H J Wanebo; S Passe; V Miké; H F Oettgen
Journal:  Cancer       Date:  1980-01-15       Impact factor: 6.860

6.  Augmentation of mouse natural killer cell activity by a streptococcal preparation, OK-432.

Authors:  K Oshimi; S Kano; F Takaku; K Okumura
Journal:  J Natl Cancer Inst       Date:  1980-12       Impact factor: 13.506

7.  Effects of corticosteroids on natural killer cell activity in systemic lupus erythematosus.

Authors:  K Oshimi; N Gonda; M Sumiya; S Kano
Journal:  Clin Exp Immunol       Date:  1980-04       Impact factor: 4.330

8.  Spontaneous cell-mediated cytotoxicity in humans. Distribution and characterization of the effector cell.

Authors:  D Santoli; G Trinchieri; L Moretta; C M Zmijewski; H Koprowski
Journal:  Clin Exp Immunol       Date:  1978-08       Impact factor: 4.330

9.  Induction and kinetics of natural killer cells in humans following interferon therapy.

Authors:  J R Huddlestone; T C Merigan; M B Oldstone
Journal:  Nature       Date:  1979-11-22       Impact factor: 49.962

10.  Anti-viral activity induced by culturing lymphocytes with tumor-derived or virus-transformed cells. Enhancement of human natural killer cell activity by interferon and antagonistic inhibition of susceptibility of target cells to lysis.

Authors:  G Trinchieri; D Santoli
Journal:  J Exp Med       Date:  1978-05-01       Impact factor: 14.307

View more
  1 in total

Review 1.  The biology of the human natural killer cell.

Authors:  J C Roder; H F Pross
Journal:  J Clin Immunol       Date:  1982-10       Impact factor: 8.317

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.